Proprotein Convertase 9
-
Subject Areas on Research
- Alirocumab after acute coronary syndrome in patients with a history of heart failure.
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
- Deep thoughts on lipids and cognition.
- Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES.
- Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
- Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.
- Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
- Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial.
- Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial.
- Exploration of PCSK9 as a Cardiovascular Risk Factor: Is There a Link to the Platelet?
- From the editor: A run of success in treating atherosclerotic vascular disease.
- From the editor: Confronting a pandemic or two.
- Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.
- Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial.
- PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.
- PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites.
- PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease.
- Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review.
- RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors.
- Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
- Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention.
- Sex-Specific Mechanisms of Resistance Vessel Endothelial Dysfunction Induced by Cardiometabolic Risk Factors.
- Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.
- The Current Evidence for Lipid Management in Patients with Lower Extremity Peripheral Artery Disease: What Is the Therapeutic Target?
- Therapy and clinical trials.
- Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained.